CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CYC

CYC - CYCLOPHARM LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.47
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.725

30 Apr
2026

-0.015

OPEN

$0.77

-2.03%

HIGH

$0.78

47,291

LOW

$0.73

TARGET
$1.00 37.9% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CYC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 15.6 - 15.0 xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A N/A xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/09 - ex-div 0.5c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-15.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx32.3 M
Book Value Per Share xxxxxxxxxxxxxxx24.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-17.3 M
Net Profit Margin xxxxxxxxxxxxxxx-53.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-49.31 %
Return on Invested Capital xxxxxxxxxxxxxxx-40.67 %
Return on Assets xxxxxxxxxxxxxxx-31.82 %
Return on Equity xxxxxxxxxxxxxxx-49.31 %
Return on Total Capital xxxxxxxxxxxxxxx-42.35 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-19.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx7 M
Total Debt xxxxxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx7 M
Price To Book Value xxxxxxxxxxxxxxx4.02

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx2.1 M
Capex % of Sales xxxxxxxxxxxxxxx6.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx34 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx17 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

23/04/2026

1

Buy

$1.00

37.93%

Cyclopharm announced a pick-up in the US rollout, with six new Technegas generators installed in 1Q26 and at least 15 more expected by June, supporting expectations of 65 units in market, Bell Potter highlights.

The broker notes the recent capital raise lifts cash to around $20m and underwrites revenue growth, with margins expected to improve towards 80% as US sales expand.

Fiscal breakeven is estimated at around 310 installed systems in the US, which could generate revenue of $19m.

Earnings forecasts are materially downgraded to reflect revised rollout assumptions and dilution from the capital raise.

Buy rating is retained, while the target price is reduced to $1.00 from $1.50.

FORECAST
Bell Potter forecasts a full year FY26 EPS of minus -15.00 cents.
Bell Potter forecasts a full year FY27 EPS of minus -8.60 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

CYC STOCK CHART

FNArena News on CYC

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia